Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 19

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 19
---
 whether and under what circumstances those securities may be held or transferred separately; |
| ● | any provision for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and                                                  |
| ● | whether the units will be issued in fully registered or global form.                                                                                                                   |

| 12 |

<div align='center'>PLAN OF DISTRIBUTION</div>

We may sell the securities from time to time, by a variety of methods, including the following:

| ● | on any national securities exchange or quotation service on which our securities may be listed at the time of sale, including Nasdaq;                                                |
| ● | in the over-the-counter market;                                                                                                                                                      |
| ● | in transactions otherwise than on such exchange or in the over-the-counter market, which may include privately negotiated transactions and sales directly to one or more purchasers; |
| ● | through ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;                                                                             |
| ● | through purchases by a broker-dealer as principal and resale by the broker-dealer for its account;                                                                                   |
| ● | through underwriters, broker-dealers, agents, in privately negotiated transactions, or any combination of these methods;                                                             |
| ● | through short sales;                                                                                                                                                                 |
| ● | through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;                                                        |
| ● | a combination of any of these methods; or                                                                                                                                            |
| ● | by any other method permitted pursuant to applicable law.                                                                                                                            |

| 13 |

The securities may be distributed from time to time in one or more transactions:

| ● | at a fixed price or prices, which may be changed;      |
| ● | at market prices prevailing at the time of sale;       |
| ● | at prices related to such prevailing market prices; or |
| ● | at negotiated prices.                                  |

A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable:

| ● | the name or names of the underwriters, dealers or agents, if any;                                                              |
| ● | the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale; |
| ● | any over-allotment or other options under which underwriters may purchase additional securities from us;                       |
| ● |